Kinetic and HPV infection effects on cross-type neutralizing antibody and avidity responses induced by Cervarix®

Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study

2010 • 2,440 citations

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women

2009 • 1,580 citations

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

2007 • 1,287 citations

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

2006 • 803 citations

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24–45 years: a randomised, double-blind trial

2009 • 468 citations

Cross-protective efficacy of two human papillomavirus vaccines: a systematic review and meta-analysis

2012 • 389 citations

MF59 Adjuvant Enhances Diversity and Affinity of Antibody-Mediated Immune Response to Pandemic Influenza Vaccines

2011 • 328 citations

Proof-of-Principle Evaluation of the Efficacy of Fewer Than Three Doses of a Bivalent HPV16/18 Vaccine

2011 • 314 citations

Antiviral antibody responses: the two extremes of a wide spectrum

2006 • 304 citations

Early high-affinity neutralizing anti-viral IgG responses without further overall improvements of affinity.

1995 • 197 citations

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica

2008 • 160 citations

HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection

2011 • 151 citations

Antibodies from Women Immunized with Gardasil ® Cross-Neutralize HPV 45 Pseudovirions

2007 • 130 citations

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

2011 • 111 citations

Co-administration of CpG oligonucleotides enhances the late affinity maturation process of human anti-hepatitis B vaccine response

2004 • 106 citations

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women

2008 • 83 citations

Cellular immune responses to HPV-18, -31, and -53 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles

2006 • 55 citations

Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals

2012 • 42 citations

The clinical benefit and cost-effectiveness of human papillomavirus vaccination for adult women in the Netherlands

2011 • 28 citations

Direct Comparison of HPV16 Serological Assays Used to Define HPV-Naïve Women in HPV Vaccine Trials

2012 • 25 citations